Injectable Drugs for Diabetes Part 6 PDF

\#\#\# \*\*Slide 44: GLP-1 Agonists (Medications)\*\* 1\. \*\*Which of the following GLP-1 agonists is derived from the saliva of the Gila monster lizard?\*\* \- A. Liraglutide (Victoza®) \- B. Exenatide (Byetta®) \- C. Dulaglutide (Trulicity®) \- D. Semaglutide (Ozempic®) \*\*Answer:\*\* B. E...

\#\#\# \*\*Slide 44: GLP-1 Agonists (Medications)\*\* 1\. \*\*Which of the following GLP-1 agonists is derived from the saliva of the Gila monster lizard?\*\* \- A. Liraglutide (Victoza®) \- B. Exenatide (Byetta®) \- C. Dulaglutide (Trulicity®) \- D. Semaglutide (Ozempic®) \*\*Answer:\*\* B. Exenatide (Byetta®) 2\. \*\*Which GLP-1 agonist has been proven to reduce major cardiovascular events and mortality in patients with type 2 diabetes?\*\* \- A. Exenatide (Byetta®) \- B. Liraglutide (Victoza®) \- C. Dulaglutide (Trulicity®) \- D. Semaglutide (Ozempic®) \*\*Answer:\*\* B. Liraglutide (Victoza®) 3\. \*\*Which of the following is a once-weekly GLP-1 agonist used for type 2 diabetes and cardiovascular risk reduction?\*\* \- A. Exenatide (Byetta®) \- B. Liraglutide (Victoza®) \- C. Dulaglutide (Trulicity®) \- D. Insulin glargine (Lantus®) \*\*Answer:\*\* C. Dulaglutide (Trulicity®) \-\-- \#\#\# \*\*Slide 45: Semaglutide (Ozempic, Rybelsus, Wegovy)\*\* 1\. \*\*What is the oral form of semaglutide used for the treatment of type 2 diabetes?\*\* \- A. Ozempic® \- B. Rybelsus® \- C. Wegovy® \- D. Byetta® \*\*Answer:\*\* B. Rybelsus® 2\. \*\*Which form of semaglutide is approved for weight management in patients with obesity and cardiovascular disease?\*\* \- A. Ozempic® \- B. Rybelsus® \- C. Wegovy® \- D. Victoza® \*\*Answer:\*\* C. Wegovy® 3\. \*\*What is the dual action mechanism of tirzepatide (Mounjaro®)?\*\* \- A. GLP-1 receptor agonist and GIP receptor agonist \- B. GLP-1 receptor agonist and DPP-4 inhibitor \- C. GLP-1 receptor agonist and alpha-glucosidase inhibitor \- D. GIP receptor agonist and insulin sensitizer \*\*Answer:\*\* A. GLP-1 receptor agonist and GIP receptor agonist \-\-- \#\#\# \*\*Slide 46: Cardiovascular Effects of GLP-1 Agonists\*\* 1\. \*\*Which of the following cardiovascular effects is associated with GLP-1 agonist therapy?\*\* \- A. Increased systolic blood pressure \- B. Decreased triglyceride levels by 20% or more \- C. Increased heart rate and triglyceride levels \- D. Decreased insulin sensitivity \*\*Answer:\*\* B. Decreased triglyceride levels by 20% or more 2\. \*\*GLP-1 agonists improve endothelial function by promoting which of the following?\*\* \- A. Vasoconstriction \- B. Vasodilation \- C. Decreased heart rate \- D. Decreased production of nitric oxide \*\*Answer:\*\* B. Vasodilation 3\. \*\*Which of the following markers of cardiovascular health are reduced by GLP-1 agonists?\*\* \- A. LDL cholesterol \- B. C-reactive protein (CRP) \- C. HDL cholesterol \- D. Apolipoprotein B \*\*Answer:\*\* B. C-reactive protein (CRP) \-\-- \#\#\# \*\*Slide 47: GLP-1 Agonists (Indications)\*\* 1\. \*\*Which of the following is an indication for GLP-1 agonist therapy?\*\* \- A. Type 2 diabetes only \- B. Type 1 and type 2 diabetes \- C. Gestational diabetes \- D. Pre-diabetes \*\*Answer:\*\* A. Type 2 diabetes only 2\. \*\*GLP-1 agonists may be combined with which of the following to help manage postprandial glucose control?\*\* \- A. Basal insulin and metformin \- B. Sulfonylureas only \- C. Insulin pumps only \- D. DPP-4 inhibitors \*\*Answer:\*\* A. Basal insulin and metformin 3\. \*\*Which of the following is a benefit of using GLP-1 agonists in patients with type 2 diabetes?\*\* \- A. Weight gain \- B. Decreased postprandial glucose levels \- C. Increased insulin resistance \- D. Increased triglycerides \*\*Answer:\*\* B. Decreased postprandial glucose levels \-\-- \#\#\# \*\*Slide 48: GLP-1 Agonist Adverse Effects\*\* 1\. \*\*Which gastrointestinal side effect is most commonly associated with GLP-1 agonist therapy?\*\* \- A. Diarrhea \- B. Nausea \- C. Vomiting \- D. Constipation \*\*Answer:\*\* B. Nausea 2\. \*\*What percentage of patients may experience nausea as a side effect of GLP-1 agonist therapy?\*\* \- A. 1-10% \- B. 11-50% \- C. 51-75% \- D. \>75% \*\*Answer:\*\* B. 11-50% 3\. \*\*Which of the following is a rare but serious adverse effect associated with GLP-1 agonists?\*\* \- A. Hypoglycemia \- B. Pancreatitis \- C. Hepatitis \- D. Renal failure \*\*Answer:\*\* B. Pancreatitis \-\-- \#\#\# \*\*Slide 49: GLP-1 Agonists -- Contraindications\*\* 1\. \*\*Which of the following is a contraindication for GLP-1 agonist therapy?\*\* \- A. Type 2 diabetes \- B. Gastroparesis \- C. Hyperthyroidism \- D. Chronic obstructive pulmonary disease \*\*Answer:\*\* B. Gastroparesis 2\. \*\*In patients with a history of pancreatitis, what is the appropriate action regarding GLP-1 agonist therapy?\*\* \- A. It should be initiated with close monitoring \- B. It is contraindicated and should be avoided \- C. The dose should be reduced \- D. It should be combined with DPP-4 inhibitors \*\*Answer:\*\* B. It is contraindicated and should be avoided 3\. \*\*For patients with renal insufficiency, which GLP-1 agonist should be used with caution due to potential gastrointestinal side effects?\*\* \- A. Exenatide \- B. Dulaglutide \- C. Liraglutide \- D. Semaglutide \*\*Answer:\*\* A. Exenatide \-\-- \#\#\# \*\*Slide 50: Amylin Analog (Pramlintide)\*\* 1\. \*\*Pramlintide (Symlin®) is an analog of which naturally occurring hormone?\*\* \- A. GLP-1 \- B. Insulin \- C. Amylin \- D. Glucagon \*\*Answer:\*\* C. Amylin 2\. \*\*Pramlintide is indicated for use in which group of patients?\*\* \- A. Type 1 and type 2 diabetes patients already on insulin \- B. Type 2 diabetes patients on oral medications only \- C. Patients with gestational diabetes \- D. Patients with pre-diabetes \*\*Answer:\*\* A. Type 1 and type 2 diabetes patients already on insulin 3\. \*\*What is a major side effect of pramlintide (Symlin®) therapy, leading to a boxed warning?\*\* \- A. Severe hypoglycemia \- B. Hyperkalemia \- C. Weight gain \- D. Hypertension \*\*Answer:\*\* A. Severe hypoglycemia 4\. \*\*When starting pramlintide, how should mealtime insulin doses be adjusted?\*\* \- A. Increased by 50% \- B. Decreased by 50% \- C. Maintained at the same dose \- D. Completely discontinued \*\*Answer:\*\* B. Decreased by 50%